IL-2-话题@MedSci

#IL-2#

62篇内容 | 1067人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183697, encodeId=422f218369e4a, content=<a href='/topic/show?id=c1414821547' target=_blank style='color:#2F92EE;'>#巨细胞病毒#</a> <a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a> <a href='/topic/show?id=175c110466a8' target=_blank style='color:#2F92EE;'>#CD4+ T细胞#</a>, objectTitle=PLoS Pathog：揭示晚起性CD4+ T 细胞对抗唾液腺中的巨细胞病毒机制, objectType=article, longId=810292, objectId=602e8102926c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240121/1705794428086_2185383.png, objectUrl=/article/show_article.do?id=602e8102926c, replyNumber=0, likeNumber=17, createdTime=2024-01-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2104915, encodeId=0e6c21049153c, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>免疫刺激性细胞因子是免疫系统的中枢调节因子，具有作为免疫治疗药物的巨大潜力。然而，其临床应用受到全身免疫激活产生的严重毒性的限制。IL-2是一种被批准用于治疗黑色素瘤和肾细胞癌的强效多效细胞因子，然而受到CD25+细胞的优先激活和全身性剂量限制毒性的影响，限制了其临床应用。最近，计算机蛋白质设计的最新进展使得能够产生高度稳定的功能性蛋白质，其完全具有天然细胞因子的活性，而且改善了生化和治疗特性。一种新设计的IL-2模拟物（Neo-2/15）通过激活IL-2Rβ和IL-2Rγ来复制IL-2和IL-15的免疫刺激功能，但完全独立于CD25和CD215受体。与天然IL-2相比，这种模拟物通过避免CD25+免疫细胞的优先激活，诱导了毒性降低的有效免疫治疗。其聚乙二醇化的版本（NL-201）已在多个临床前模型中显示出改善的治疗效果，目前正在临床试验中进行测试。, objectTitle=IL-2, objectType=topic, longId=9652, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=40, createdTime=2022-12-08, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1626079, encodeId=cbf716260e9e4, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=ARD：低剂量白细胞介素 2 治疗活动性系统性红斑狼疮 (LUPIL-2)有益, objectType=article, longId=739085, objectId=e5f4e390855c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5f4e390855c, replyNumber=0, likeNumber=50, createdTime=2022-09-13, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5f4e390855c, moduleTitle=ARD：低剂量白细胞介素 2 治疗活动性系统性红斑狼疮 (LUPIL-2)有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5f4e390855c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626078, encodeId=410e16260e842, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, objectType=article, longId=736657, objectId=c691e366579d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c691e366579d, replyNumber=0, likeNumber=56, createdTime=2022-08-24, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c691e366579d, moduleTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c691e366579d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626077, encodeId=ec6116260e768, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, objectType=article, longId=725659, objectId=d704e2565909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d704e2565909, replyNumber=0, likeNumber=48, createdTime=2022-04-29, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d704e2565909, moduleTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d704e2565909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626076, encodeId=41b016260e62c, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Nature：暨南大学尹芝南团队发现，IL-27能促进白色脂肪棕色化产热，燃烧你的卡路里！, objectType=article, longId=292275, objectId=87572922e5ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87572922e5ca, replyNumber=0, likeNumber=49, createdTime=2021-12-22, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87572922e5ca, moduleTitle=Nature：暨南大学尹芝南团队发现，IL-27能促进白色脂肪棕色化产热，燃烧你的卡路里！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87572922e5ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626075, encodeId=b51a16260e58a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效, objectType=article, longId=220861, objectId=4919220861ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4919220861ca, replyNumber=0, likeNumber=47, createdTime=2021-11-24, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4919220861ca, moduleTitle=Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4919220861ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626074, encodeId=efcc16260e494, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=J Invest Dermatol ：通过激活IL-22受体下游的信号治疗银屑病的研究, objectType=article, longId=219396, objectId=5520219396cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5520219396cb, replyNumber=0, likeNumber=38, createdTime=2021-10-29, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5520219396cb, moduleTitle=J Invest Dermatol ：通过激活IL-22受体下游的信号治疗银屑病的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5520219396cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626073, encodeId=2c1c16260e339, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, objectType=article, longId=216683, objectId=469921668328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=469921668328, replyNumber=0, likeNumber=40, createdTime=2021-09-05, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=469921668328, moduleTitle=JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=469921668328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626072, encodeId=16e516260e2d7, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=J Immunol Res：IL-27对过敏性鼻炎中II型先天淋巴细胞反应的抑制研究, objectType=article, longId=205421, objectId=e0ef2054219a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0ef2054219a, replyNumber=0, likeNumber=35, createdTime=2021-01-08, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0ef2054219a, moduleTitle=J Immunol Res：IL-27对过敏性鼻炎中II型先天淋巴细胞反应的抑制研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0ef2054219a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626071, encodeId=e33e16260e1b8, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Cell Death Differ：IL-24缺失抑制IL-4诱导的巨噬细胞M2型转化以预防肺纤维化作用, objectType=article, longId=203368, objectId=0aec2033689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aec2033689c, replyNumber=0, likeNumber=40, createdTime=2020-11-15, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aec2033689c, moduleTitle=Cell Death Differ：IL-24缺失抑制IL-4诱导的巨噬细胞M2型转化以预防肺纤维化作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aec2033689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626070, encodeId=28e116260e04d, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎, objectType=article, longId=203361, objectId=d59f203361c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d59f203361c6, replyNumber=0, likeNumber=30, createdTime=2020-11-15, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d59f203361c6, moduleTitle=Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d59f203361c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626069, encodeId=f3cd162606916, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, objectType=article, longId=202204, objectId=7085202204a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7085202204a8, replyNumber=0, likeNumber=45, createdTime=2020-10-18, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7085202204a8, moduleTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7085202204a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626068, encodeId=bd71162606874, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增, objectType=article, longId=201064, objectId=c86e201064d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86e201064d5, replyNumber=0, likeNumber=49, createdTime=2020-09-24, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86e201064d5, moduleTitle=Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86e201064d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626067, encodeId=74e9162606e53, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Nat Commun：抗IL-20单抗7E或可成为胰腺癌的新型靶向药物, objectType=article, longId=200861, objectId=778c200861d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=778c200861d3, replyNumber=0, likeNumber=38, createdTime=2020-09-19, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=778c200861d3, moduleTitle=Nat Commun：抗IL-20单抗7E或可成为胰腺癌的新型靶向药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=778c200861d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626066, encodeId=aa3a162606613, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=39, createdTime=2020-08-03, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626065, encodeId=e1e916260658a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=44, createdTime=2020-07-20, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626064, encodeId=91d11626064cf, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=JCC：锌缺乏会激活IL-23 / Th17轴从而加剧实验性结肠炎, objectType=article, longId=197406, objectId=2a1319e40649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a1319e40649, replyNumber=0, likeNumber=45, createdTime=2020-07-14, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a1319e40649, moduleTitle=JCC：锌缺乏会激活IL-23 / Th17轴从而加剧实验性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a1319e40649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626063, encodeId=529c162606377, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=46, createdTime=2020-06-29, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性, objectType=article, longId=196440, objectId=917e19644006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=917e19644006, replyNumber=0, likeNumber=32, createdTime=2020-06-26, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=917e19644006, moduleTitle=Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917e19644006)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#巨细胞病毒# #IL-2# #CD4+ T细胞#

2024-01-24发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #IL-2#免疫刺激性细胞因子是免疫系统的中枢调节因子，具有作为免疫治疗药物的巨大潜力。然而，其临床应用受到全身免疫激活产生的严重毒性的限制。IL-2是一种被批准用于治疗黑色素瘤和肾细胞癌的强效多效细胞因子，然而受到CD25+细胞的优先激活和全身性剂量限制毒性的影响，限制了其临床应用。最近，计算机蛋白质设计的最新进展使得能够产生高度稳定的功能性蛋白质，其完全具有天然细胞因子的活性，而且改善了生化和治疗特性。一种新设计的IL-2模拟物（Neo-2/15）通过激活IL-2Rβ和IL-2Rγ来复制IL-2和IL-15的免疫刺激功能，但完全独立于CD25和CD215受体。与天然IL-2相比，这种模拟物通过避免CD25+免疫细胞的优先激活，诱导了毒性降低的有效免疫治疗。其聚乙二醇化的版本（NL-201）已在多个临床前模型中显示出改善的治疗效果，目前正在临床试验中进行测试。

2022-12-08

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

ARD：低剂量白细胞介素 2 治疗活动性系统性红斑狼疮 (LUPIL-2)有益

2022-09-13

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率

2022-08-24

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究

2022-04-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Nature：暨南大学尹芝南团队发现，IL-27能促进白色脂肪棕色化产热，燃烧你的卡路里！

2021-12-22

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效

2021-11-24

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

J Invest Dermatol ：通过激活IL-22受体下游的信号治疗银屑病的研究

2021-10-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

JAMA：IL-23 抑制剂Risankizumab 对中度至重度银屑病患者治疗结果的影响

2021-09-05

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

J Immunol Res：IL-27对过敏性鼻炎中II型先天淋巴细胞反应的抑制研究

2021-01-08

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Cell Death Differ：IL-24缺失抑制IL-4诱导的巨噬细胞M2型转化以预防肺纤维化作用

2020-11-15

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎

2020-11-15

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率

2020-10-18

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Blood：维甲酸反应性CD8效应T细胞在胃肠GvHD富含IL-23的组织中选择性扩增

2020-09-24

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Nat Commun：抗IL-20单抗7E或可成为胰腺癌的新型靶向药物

2020-09-19

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-08-03

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

JCC：锌缺乏会激活IL-23 / Th17轴从而加剧实验性结肠炎

2020-07-14

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2020-06-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性

2020-06-26

科室
- - 订阅+
  - 更多科室
工具
服务